High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study

Hepatology International

Volumn 10, Issue 2, 2016, Pages 310-319

  Petersen, Tess ^a   Townsend, Kerry ^b   Gordon, Lori A ^c,d   Sidharthan, Sreetha ^a   Silk, Rachel ^a,e   Nelson, Amy ^e   Gross, Chloe ^e,f   Calderón, Monica ^f,g   Proschan, Michael ^b   Osinusi, Anu ^b,e,h   Polis, Michael A ^b   Masur, Henry ^a   Kottilil, Shyam ^b,e,j   Kohli, Anita ^a,f,i  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d XAVIER UNIVERSITY OF LOUISIANA   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

^f FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^g CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^h GILEAD SCIENCES   (United States)

ⁱ CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Adherence; DAA; HCV; MEMS

Indexed keywords

ANTIVIRUS AGENT; LEDIPASVIR PLUS SOFOSBUVIR; RADALBUVIR; VEDROPREVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; CITY; CONTROLLED STUDY; DEPRESSION; DRUG CAPSULE; DRUG USE; EVENING DOSAGE; FEMALE; GENOTYPE; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIDDLE AGED; MORNING DOSAGE; PATIENT COMPLIANCE; PILL; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; SYMPTOMATOLOGY; URBAN POPULATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; HEPATITIS C, CHRONIC; MEDICATION COMPLIANCE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; TREATMENT OUTCOME; URBAN POPULATION;

EID: 84959494414     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-015-9680-7     Document Type: Article

References (30)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128.
2. Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384:1597–1605.
3. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–1898.
4. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383:515–523.
5. Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. New Engl J Med. 2014;370:222–232.
6. Hubbard T, McNeill N. Thinking outside the pillbox: a system-wide approach to improving patient medication adherence for chronic disease. Accessed 9 December 2014.
7. Sanjuan R, Nebot MR, Chirico N, Mansky LM, Belshaw R. Viral mutation rates. J Virol. 2010;84:9733–9748.
8. Friedland GH, Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS. 1999;13(Suppl 1):S61–S72.
9. Harvoni (R) (ledipasvir and sofosbuvir) [package insert]. http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf. Accessed December 2 2014.
10. Nelson D, Yoshida EM, Paulson MS, et al. Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor. Antiviral Therapy. 2014;19:679–686.
11. Finance DDo. Clinical Criteria for Approving Sovaldi.
12. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061–1069.
13. Cuevas JM, Torres-Puente M, Jimenez-Hernandez N, et al. Combined therapy of interferon plus ribavirin promotes multiple adaptive solutions in hepatitis C virus. J Med Virol. 2009;81:650–656.
14. Paolucci S, Fiorina L, Mariani B, et al. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients. Virol J. 2013;10:355.
15. Kohli A, Osinusi A, Sims Z, et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet. 2015;385:1107–1113.
16. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000;12:255–266.
17. Mirowsky J, Ross CE. Age and depression. J Health Soc Behav. 1992; 33:187–205; discussion 6–12
18. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24:385–396.
19. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–1982.
20. Jensen D, O’Leary J, Pockros PJ. Safety and Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C: Real-World Experience In A Diverse, Longitudinal Observational Cohort. [Abstract nr. 45]. American Association for the Study of Liver Diseases (AASLD) Liver Meeting. Boston, MA
21. Dieterich D, Bacon B, Flamm S. Evaluation of Sofosbuvir and Simeprevir-Based Regimens in the TRIO network: academic and community treatment of a real-world heterogeneous population. [Abstract nr. 46]. American Association for the Study of Liver Diseases (AASLD) Liver Meeting. Boston, MA
22. Kosaka K, Imamura M, Hayes CN, et al. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1. J Viral Hepat. 2014;22:158–165.
23. Tsui JI, Maselli J, Gonzales R. Sociodemographic trends in national ambulatory care visits for hepatitis C virus infection. Dig Dis Sci. 2009;54:2694–2698.
24. Mathes T, Antoine SL, Pieper D. Factors influencing adherence in Hepatitis-C infected patients: a systematic review. BMC Infect Dis. 2014;14:203.
25. Lewey J, Shrank WH, Bowry AD, Kilabuk E, Brennan TA, Choudhry NK. Gender and racial disparities in adherence to statin therapy: a meta-analysis. Am Heart J 2013; 165:665–678, 78 e1
26. Nelson A. Impact of pre-existing mental health disorders on adherence and sustained virologic response with an interferon-free trial of sofosbuvir and ribavirin for chronic Hepatitis C. AASLD 2013; Abstract 319.
27. Wagner GJ, Rabkin JG. Measuring medication adherence: are missed doses reported more accurately then perfect adherence? AIDS Care. 2000;12:405–408.
28. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497.
29. Jin J, Sklar GE, Oh VMS, Li SC. Factors affecting therapeutic compliance: a review from the patient’s perspective. Ther Clin Risk Manag. 2008;4:269–286.
30. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–1888.